Liquidity
Strong32.05
How the figure is assessed
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
Org. no. 984 276 141 · Private limited company (AS) · Active · c/o Torgeir Vaage, Gabels gate 43A, 0262, OSLO · OSLO · 21.200 – Manufacture of pharmaceutical preparations
CAERUS CAPITAL AS is a private limited company (as) registered in OSLO since 2001. The organisation number is 984 276 141. The latest submitted annual accounts are for 2025.
Source: The Brønnøysund Register Centre · Last updated 22 November 2026 at 09:27
Quick overview
Based on the latest submitted annual accounts (2025) and registry data.
32.05
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
96.2 %
Operating profit divided by operating revenue. Below 0% is weak, 0–10% needs attention and 10% or more is strong.
97 %
Equity divided by assets. Below 10% is weak, 10–30% needs attention and 30% or more is strong.
Calculated by us
Based on status, solvency, liquidity, profitability, trend and how recent the accounts are. Public register data only.
This is an indicative assessment, not a credit rating. It does not replace your own due diligence before entering into an agreement.
Proffi+
Calculating …
Indicative model estimate based on public accounting figures and typical industry multiples. Not an appraisal, a valuation or investment advice.
Development
Revenue and profit
RevenueResult
Development
Solvency and profitability (%)
SolidityProfitability
Registry data
Addresses
Not registered
Industry
Manufacture of pharmaceutical preparations(main industry)
C Manufacturing › 21 Manufacture of basic pharmaceutical products and pharmaceutical preparations › 21.2 Manufacture of pharmaceutical preparations › 21.20 Manufacture of pharmaceutical preparations
See the industry: largest companies and key figures →Inkluderer: Omfatter produksjon av legemidler: antisera og andre blodfraksjoner, vaksiner, diverse legemidler herunder homøopatiske preparater, kjemiske svangerskapsforebyggende produkter til utvendig bruk og hormonelle svangerskapsforebyggende legemidler, sement til beinoppbygging, medisinske diagnostiseringspreparater herunder graviditetstester, radioaktive in-vivo diagnostiseringsstoffer og bioteknologiske medisiner Inkluderer også: Omfatter også produksjon av medisinsk impregnert vatt, gas, bandasjer, forbindinger mv. og bearbeiding av plantevekster til medisinsk bruk (knusing, sortering, formaling) Ekskluderer: Produksjon av planteuttrekk (mint, verbena, kamille mv.) grupperes under: 10.83 Bearbeiding av te og kaffe. Produksjon av tannfyllinger og produksjon av dental sement grupperes under: 32.50 Produksjon av medisinske og tanntekniske instrumenter og utstyr. Produksjon av kirurgisk forheng grupperes under: 32.50 Produksjon av medisinske og tanntekniske instrumenter og utstyr. Produksjon av sement til rekonstruksjon av bein grupperes under: 32.50 Produksjon av medisinske og tanntekniske instrumenter og utstyr. Engroshandel med apotekvarer grupperes under: 46.46 Engroshandel med sykepleie- og apotekvarer. Butikkhandel med apotekvarer grupperes under: 47.73 Butikkhandel med apotekvarer. Forskning og utvikling av apotekvarer og bioteknologiske apotekvarer grupperes under: 72.1 Forskning og utviklingsarbeid innen naturvitenskap og teknikk. Pakking av apotekvarer grupperes under: 82.92 Pakkevirksomhet
Institutional sector code: Private aksjeselskaper mv. (2100)
Produktutvikling i farmasøytisk industri, konsulentvirksomhet, investeringsvirksomhet samt deltakelse i andre foretak.
Registry status
Experiences
Loading reviews …
You must sign in with a verified email to write a review.
Financial overview
Fiscal year 2025 · Amounts in NOK
Data basis
3 stored years
32.05
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
96.2 %
Operating profit divided by operating revenue. Below 0% is weak, 0–10% needs attention and 10% or more is strong.
97 %
Equity divided by assets. Below 10% is weak, 10–30% needs attention and 30% or more is strong.
Only reported amounts from the Register of Company Accounts
| Accounting item | 2025 | 2024 | 2023 | Development |
|---|---|---|---|---|
| Operating revenue | 1,681,104 | 1,589,969 | 1,237,928 | |
| Operating profit | 1,617,566 | 1,558,792 | 1,215,700 | |
| Profit before tax | 2,476,890 | 2,600,868 | 2,722,406 | |
| Net result | 2,212,949 | 2,600,868 | 2,722,406 | |
| Total assets | 10,604,506 | 9,669,476 | 8,979,535 | |
| Equity | 10,291,147 | 8,078,199 | 5,477,331 | |
| Liabilities | 313,359 | 1,591,277 | 3,502,205 |
Graphical analysis
Amounts in NOK
Calculated by us, in percent
Balance sheet in NOK
Register of Company Accounts
Period 2025-01-01 to 2025-12-31. Currency NOK. Audited annual accounts. Virksomheten har fravalgt revisjon.
| Total operating revenue | 1,681,104 NOK |
|---|---|
| Total operating expenses | 63,538 NOK |
| Operating profit | 1,617,566 NOK |
| Total financial income | 907,157 NOK |
| Total financial expenses | 47,833 NOK |
| Net financial items | 859,324 NOK |
| Profit before tax | 2,476,890 NOK |
| Net result | 2,212,949 NOK |
| Total fixed assets | 881,027 NOK |
|---|---|
| Total current assets | 9,723,479 NOK |
| Total assets | 10,604,506 NOK |
| Paid-in equity | 3,438,652 NOK |
|---|---|
| Retained earnings | 6,852,495 NOK |
| Total equity | 10,291,147 NOK |
| Current liabilities | 303,359 NOK |
| Long-term liabilities | 10,000 NOK |
| Total debt | 313,359 NOK |
| Total equity and liabilities | 10,604,506 NOK |
Register of Company Accounts
Period 2024-01-01 to 2024-12-31. Currency NOK. Audited annual accounts. Virksomheten har fravalgt revisjon.
| Total operating revenue | 1,589,969 NOK |
|---|---|
| Total operating expenses | 31,177 NOK |
| Operating profit | 1,558,792 NOK |
| Total financial income | 2,202,491 NOK |
| Total financial expenses | 1,160,415 NOK |
| Net financial items | 1,042,076 NOK |
| Profit before tax | 2,600,868 NOK |
| Net result | 2,600,868 NOK |
| Total fixed assets | 0 NOK |
|---|---|
| Total current assets | 9,669,476 NOK |
| Total assets | 9,669,476 NOK |
| Paid-in equity | 3,438,652 NOK |
|---|---|
| Retained earnings | 4,639,547 NOK |
| Total equity | 8,078,199 NOK |
| Current liabilities | 38,086 NOK |
| Long-term liabilities | 1,553,191 NOK |
| Total debt | 1,591,277 NOK |
| Total equity and liabilities | 9,669,476 NOK |
Register of Company Accounts
Period 2023-01-01 to 2023-12-31. Currency NOK. Audited annual accounts. Virksomheten har fravalgt revisjon.
| Total operating revenue | 1,237,928 NOK |
|---|---|
| Total operating expenses | 22,228 NOK |
| Operating profit | 1,215,700 NOK |
| Total financial income | 1,595,459 NOK |
| Total financial expenses | 88,753 NOK |
| Net financial items | 1,506,706 NOK |
| Profit before tax | 2,722,406 NOK |
| Net result | 2,722,406 NOK |
| Total fixed assets | 0 NOK |
|---|---|
| Total current assets | 8,979,535 NOK |
| Total assets | 8,979,535 NOK |
| Paid-in equity | 3,438,652 NOK |
|---|---|
| Retained earnings | 2,038,679 NOK |
| Total equity | 5,477,331 NOK |
| Current liabilities | 228,682 NOK |
| Long-term liabilities | 3,273,523 NOK |
| Total debt | 3,502,205 NOK |
| Total equity and liabilities | 8,979,536 NOK |
Source: Register of Company Accounts, Brønnøysund Register Centre. Figures are shown as submitted, and historical years are never overwritten by newer submissions.
Calculated by us
| Key figures | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue growthChange in total operating revenue from the previous fiscal year. | 5.7 % | 28.4 % | – |
| Operating marginOperating profit divided by total operating revenue. | 96.2 % | 98 % | 98.2 % |
| Profit marginOrdinary profit before tax divided by total operating revenue. | 147.3 % | 163.6 % | 219.9 % |
| Equity ratioTotal equity divided by total assets. | 97 % | 83.5 % | 61 % |
| Current ratioTotal current assets divided by total current liabilities. | 32.05 | 253.89 | 39.27 |
| Debt ratioTotal liabilities divided by total equity. | 0.03 | 0.2 | 0.64 |
| Return on assetsOrdinary profit before tax plus financial expenses, divided by total assets. | 23.8 % | 38.9 % | 31.3 % |
| Return on equityNet profit divided by total equity. | 21.5 % | 32.2 % | 49.7 % |
About the calculation
The key figures are calculated by us (formula version v1) from public accounts in the Register of Company Accounts. A figure is only calculated when all input values exist and the denominator is not zero. The figures are not a credit assessment.
Registry data
Source: The Brønnøysund Register Centre. We only show name and role as published by the register – never date of birth or private address.
Structure
Overview
CAERUS CAPITAL AS
OSLO
Registry data
| Name | Org. no. | Place | Employees |
|---|---|---|---|
| CAERUS CAPITAL ASManufacture of pharmaceutical preparations | 931 489 348 | OSLO | – |
This has not been registered yet. We never show made-up information.
Services and products
The company has not added any services yet.
Public approvals
Not in the Norwegian Building Authority's central approval register.
Public contracts
No notices found in TED where the company is a supplier or contracting authority.
Registered changes
We show changes from the Brønnøysund Register Centre's change log from the next registered change.
Documents
Certificates of registration and other documents require a separate agreement with a document provider.
Transparency
Company information
Brønnøysund Register Centre · Public register
Last retrieved 22 November 2026 at 09:27
Open official sourceRoles
Brønnøysund Register Centre · Public register
Last retrieved 22 November 2026 at 09:27
Open official sourceAccounts and key figures
Register of Company Accounts · Public register
Last retrieved 22 November 2026 at 09:27
Open official sourceCentral approval
Norwegian Building Authority (DiBK) · No approval found
Last retrieved 22 November 2026 at 09:27
Open official sourceIndustry standard (SN2007)
Statistics Norway – KLASS · Official standard
Last retrieved 22 November 2026 at 09:27
Open official sourcePublic registry data is updated periodically and cannot be changed by the company. Calculated figures are marked “Calculated by us”.
Report an errorSource
Public registry fields on this page come from the Central Coordinating Register and cannot be changed by the company. Self-reported content is marked separately.
Read about the data sourcesTalk to Proffi
Leave your contact details and an adviser will explain how segmentation, company profiles and supplier search can support your business.